Profund Advisors LLC Sells 2,815 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Profund Advisors LLC decreased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 25.6% in the second quarter, Holdings Channel.com reports. The firm owned 8,187 shares of the company’s stock after selling 2,815 shares during the period. Profund Advisors LLC’s holdings in Mirum Pharmaceuticals were worth $417,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MIRM. CWM LLC raised its position in Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company’s stock worth $27,000 after purchasing an additional 428 shares during the period. Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the last quarter. Quarry LP purchased a new position in shares of Mirum Pharmaceuticals in the first quarter worth about $56,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 14.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock worth $97,000 after buying an additional 248 shares during the period. Finally, Avanza Fonder AB lifted its stake in shares of Mirum Pharmaceuticals by 44.3% in the 2nd quarter. Avanza Fonder AB now owns 4,154 shares of the company’s stock valued at $211,000 after acquiring an additional 1,276 shares during the last quarter.

Wall Street Analysts Forecast Growth

MIRM has been the topic of several recent research reports. TD Cowen upgraded Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, September 25th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Stifel Nicolaus set a $89.00 target price on shares of Mirum Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Wednesday, October 8th. Finally, JMP Securities set a $95.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $84.91.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 9,578 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $76.01, for a total transaction of $728,023.78. Following the transaction, the chief financial officer owned 39,945 shares in the company, valued at approximately $3,036,219.45. This represents a 19.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Laura Brege sold 17,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $74.40, for a total value of $1,264,800.00. Following the completion of the transaction, the director owned 15,703 shares of the company’s stock, valued at approximately $1,168,303.20. The trade was a 51.98% decrease in their position. The SEC filing for this sale provides additional information. 14.36% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $69.25 on Friday. The firm has a market capitalization of $3.56 billion, a price-to-earnings ratio of -80.52 and a beta of 0.75. The stock has a fifty day moving average of $72.63 and a 200 day moving average of $59.78. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $78.54. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company’s quarterly revenue was up 47.1% compared to the same quarter last year. During the same period last year, the company posted ($0.30) EPS. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.